杂志简称：atherosclerosis supp
中文译名：《动脉粥样硬化+》
收录属性：scie（2024版）, 英文期刊,
自引率：1.80%
投稿方向：医学、peripheral vascular disease 外周血管病
SCI/E期刊基本信息
出版周期：季刊 地区：爱尔兰
中科院分区：2区
是否TOP：非TOP期刊
是否综述：非综述期刊
是否OA：非OA期刊
国际标准刊号：ISSN2667-0895；E-ISSN1878-5050
杂志语言：英语
出版国家：爱尔兰
杂志官网 联系方式
出版地址：ELSEVIER IRELAND LTD,ELSEVIER HOUSE,BROOKVALE PLAZA,EAST PARK SHANNON,CO,CLARE,IRELAND,00000
杂志邮箱：
投稿网址：https://www.editorialmanager.com/athplu/default.aspx
杂志官方网址：https://www.journals.elsevier.com/atherosclerosis-plus
出版商网址：http://www.elsevier.nl
杂志投稿要求
投稿须知【杂志社官方网站信息】
Guide for Authors
Atherosclerosis Plus is a fully electronic journal, all manuscripts are to be submitted online at https://www.editorialmanager.com/athplu/default.aspx.
Types of papers that can be submitted for consideration by the Editorial Board include:
Original Research Papers
Original Research Papers are divided into three categories:
Basic Research Papers reporting results of original research or investigation using in vitro cell culture or animal models.
Clinical and Population Research Papers reporting results of investigation in human subjects including observational, interventional and genetic studies. Meta-analyses and genetic association studies will also be published under this category. For publication of clinical trials, genetic association studies and meta-analyses, please consult the dedicated Special Guidelines below.
Translational Research Papers reporting results of research from both bench-to-bedside and bedside-to-bench.
The following word limits apply: abstract 250 words, main text 4000 words (including legends to figures and tables), 5 figures and/or tables in total (authors are encouraged to include additional figures and tables as Supplementary Material) and a maximum of 50 references. Flexibility on word count may be offered after discussion with the Editor.
Short Communications. Usually under 2000 words plus 1-2 tables/figures and references.
Case Reports. Case reports are limited to 4 authors, 8 double-spaced pages total, including text, references (less than 20), figure legends, and 4 figures. No abstract included.
Review Articles
Atherosclerosis publishes review articles on topics of great interest or controversy in basic, translational, clinical or population research. Authors who have not been priorly invited to submit a Review by the Editors of Atherosclerosis are advised to write a letter of interest to the Editorial Office, accompanied by an abstract. Based on this, the Editors will encourage or discourage submission. Please note that we only consider Reviews from authors who contributed significant original research to the reviewed research field; a list of previously published works should be provided in the cover letter. In all cases, Review Articles undergo peer review. The following word limits apply: abstract 250 words, main text 5000 words, 6 figures and/or tables in total, and a maximum of 100 references. Authors are encouraged to include a "mechanism/overview" figure and one or more bullet point boxes highlighting the main key-points.
Editorials and Correspondence
Editorials will be commissioned by the Editors, who will approach a suitably qualified author to write a commentary on a recently accepted Original Research Paper of particular interest. Editorials should not exceed 1500 words and 20 references. 1 figure or table is allowed.
If you have specific issues that you wish to raise concerning work published in Atherosclerosis, please submit your opinions as a Correspondence. Correspondence articles should not exceed 1000 words (including references), 10 references and 2 figures and/or tables. The inclusion of novel data will increase the chance of acceptance. The Author(s) of the commented manuscript will have the opportunity to respond to the comments in the same issue of the Journal. Please submit Correspondence to the Editor-in-Chief.
Submission declaration
Submission of an article to Atherosclerosis Plus implies that the work described has not been published previously, except in the form of an abstract or as part of a published lecture or academic thesis.
Submission of an article therefore means:
The article is not under consideration for publication elsewhere.
Publication of the article is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out.
If the article is accepted, it will not be published elsewhere by the authors, including electronically in the same form, in English or in any other language, without the written consent of the copyright-holder.
Atherosclerosis Plus will not tolerate plagiarism in any form in submitted manuscripts. Passages of text, data or figures quoted or closely paraphrased from other authors (or from any part of the author's own published work) must be identified as quotations or paraphrases and the sources of such material must be acknowledged. The use of unacknowledged material will be construed as plagiarism. If any manuscript is found to contain plagiarised material the review process will be halted immediately, and the University or Institute of the corresponding Author will be informed.
Atherosclerosis Plus will not tolerate manipulation or enhancement of data. Authors will be asked to provide further evidence for the validity of data, and the University or Institute of the corresponding Author will be informed if such evidence is not forthcoming.
Ethics in publishing
Please see our information on Ethics in publishing.
Atherosclerosis Plus will not tolerate plagiarism in any form in submitted manuscripts. Text copied from copyrighted works from third parties or from the author's own published work, in any section of the manuscript, is unacceptable. Each submission to Atherosclerosis Plus undergoes a check for plagiarism. Manuscripts with excessive overlap with previously published articles are rejected without peer review. To avoid the overlap between your manuscript and previously published works, please cite the relevant articles as references.
Declaration of competing interest
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors should complete the declaration of competing interest statement using this template and upload to the submission system at the Attach/Upload Files step. Note: Please do not convert the .docx template to another file type. Author signatures are not required. If there are no interests to declare, please choose the first option in the template. More information.
Studies involving humans
Manuscripts reporting data from research conducted on humans must include a statement of assurance in the Materials and methods section of the manuscript reading that: (1) written informed consent was obtained from each patient included in the study, (2) the study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki and (3) the study protocol has been priorly approved by the Institution's ethics committee on research on humans.
Identifying information shall not be included in any part of the paper, unless it is essential for scientific purposes and written informed consent for publication in print and electronic version has been obtained. If such consent has not been obtained, personal details of patients included in any part of the paper and in any Supplementary Material must be removed from the submission.
If identifying characteristics are altered to protect anonymity, authors should provide assurance that alterations do not distort scientific meaning and editors should note so. For publication of clinical trials, please consult the dedicated Special Guidelines below.
Studies involving animals
All experiments on live vertebrates or higher invertebrates must be performed in accordance with relevant institutional and national guidelines and regulations. A statement identifying the committee approving the experiments and confirming that all experiments conform to the relevant regulatory standards must be included in the Materials and methods section of the submission. We suggest that researchers carrying out experiments with animals refer to the ARRIVE guidelines and recommendations developed by the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) to improve experimental design and reporting of animal research.
Use of inclusive language
Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive.
Article transfer service
This journal is part of our Article Transfer Service. This means that if the Editor feels your article is more suitable in one of our other participating journals, then you may be asked to consider transferring the article to one of those. If you agree, your article will be transferred automatically on your behalf with no need to reformat. Please note that your article will be reviewed again by the new journal. More information.
Elsevier supports responsible sharing
Find out how you can share your research published in Elsevier journals.
Open access
Please visit our Open Access page for more information.